2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Gastrointestinal
1
Conditions
Venous Thrombosis
2
Venous Thromboembolism
2
Pulmonary Embolism
2
Gastrointestinal Neoplasms
1
Interventions
Dalteparin
11
apixaban
10
Tinzaparin
5
Enoxaparin
5
Rivaroxaban
4
Heparin, Low-Molecular-Weight
3
Dabigatran
3
edoxaban
2
bemiparin
2
abelacimab
2
Warfarin
2
MAA868
2
Fondaparinux
2
perflutren
1
isoquercitrin
1
enoxaparin sodium
1
Sulfur Hexafluoride
1
Rosuvastatin Calcium
1
Phenprocoumon
1
Nephrectomy
1
Nadroparin
1
Hospitals
1
Heparin
1
Fluorodeoxyglucose F18
1
Educational Status
1
Drug Delivery Systems
1
Deoxyribonucleases
1
Aspirin
1
Acetylcysteine
1
Acenocoumarol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Pulmonary Embolism
×
abelacimab
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled